Ortivus

October – December 2024

• Net sales increased by 10% and amounted to SEK 21.3 (19.4) million.
• The gross margin decreased to 21% (28%).
• Adjusted gross margin* amounted to 47% (28%).
• EBITDA amounted to SEK -4.4 (-1.2) million.
• Adjusted EBITDA* amounted to SEK 2.3 (0.2) million.
• Earnings after tax amounted to SEK -9.6 (-2.8) million.
• Earnings after tax per share before and after dilution amounted to SEK -0.22 (-0.06).

January - December 2024

• Net sales fell by 5% and amounted to SEK 80.4 (84.7) million.
• The gross margin amounted to 35% (37%).
• Adjusted gross margin* amounted to 42% (37%).
• EBITDA amounted to SEK -13.8 (-11.9) million.
• Adjusted EBITDA* amounted to SEK -4.9 (-3.7) million.
• Profit after tax amounted to SEK -24.9 (-18.2) million.
• Profit after tax per share before and after dilution amounted to -0.56 (-0.41) SEK.

Significant events during and after fourth quarter

• The exchange transfer to Nasdaq First North Growth Market was carried out on 19 December 2024.
• Impairments of inventory, customer projects, and financial assets were carried out during the quarter by SEK 8,5 million which affected the results but not the cash flow.
• With the delivery of MobiMed 5 and its integration with the Cambio Cosmic medical record system, a significant step was taken towards providing a comprehensive solution for pre-hospital care.
• A new contract was signed after the period with a new customer, East Midlands Ambulance Service NHS Trust (EMAS). The contract strengthens Ortivus presence in the UK and refers to the delivery of a digital system for the management of controlled drugs. The contract is valid for at least three years and is expected to generate revenue of just over SEK 3,6 million.
• The current credit framework with its main owner Ponderus Invest AB was extended to 31 December 2026.
• In February Gabriel Åhbeck joined as CTO and Emma Mattsson joined as CMO.